DURECT Corp - Company Profile
Powered by 
All the data and insights you need on DURECT Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date DURECT Corp Strategy Report
- Understand DURECT Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
The following section provides information on DURECT Corp’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into DURECT Corp's management and employees, unlock the full data with our company analytics monitoring tool.
Executives
Gail Maderis
Chairman Executive BoardMs. Gail Maderis has been the Chairman of the company since March 2023. Prior to this, she served as a President and Chief Executive Officer of the Antiva Biosciences July 2015 to February 2023. Previously, she served as a President and Chief Executive Officer of BayBio from October 2009 to March 2015 and President and Chief Executive Officer of Five Prime Therapeutics from 2003 to 2009. Previously she served at Genzyme Molecular Oncology, Genzyme Corporation, Genzyme Corporation and Bain & Company.
James E. Brown, D.V.M.
Chief Executive Officer; Director; President Executive BoardMr. James E. Brown has been the President, the Chief Executive Officer and Director of the company since 1998. Prior to this, he was the Vice President of Biopharmaceutical and Implant Research and Development. He also served at various positions of Syntex Corporation including the Director of Business Development, the Director of Joint Ventures for Discovery Research and also as a Program Director for Syntex Research and Development.
Timothy M. Papp, M.B.A.
Chief Financial Officer Senior ManagementMr. Timothy M. Papp has been the Chief Financial Officer of the company since July 2022. Prior to this he served as a Managing Director of RBC Capital Markets. Previously he served as a Managing Director of at Stifel. Previously he served at Cowen, Keybanc Capital Markets, and Rodman & Renshaw.
Norman L. Sussman, M.D., FAASLD
Chief Medical Officer Senior ManagementDr. Norman Sussman serves as Chief Medical Officer at the company since 2020. Prior to this, he served as Associate Professor of Medicine and Surgery at Baylor College of Medicine. Previously, he also worked with Amphioxus Cell Technologies and Hepatix, Inc.
Jian Li, M.B.A.
Vice President - Finance; Controller Senior ManagementStill looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer